Severe Cerebral White Matter Hyperintensities Predict Severe Cognitive Decline in Patients With Cerebrovascular Disease History
-
- Carole Dufouil
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Ophélia Godin
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- John Chalmers
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Oghuzan Coskun
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Stephen MacMahon
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Nathalie Tzourio-Mazoyer
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Marie-Germaine Bousser
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Craig Anderson
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Bernard Mazoyer
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
-
- Christophe Tzourio
- From Inserm, U708 (C.D., O.G., C.T.), Paris, France; Université Pierre et Marie Curie-Paris6 (C.D., O.G., C.T.), Paris, France; The George Institute for International Health (J.C., S.M., C.A.), Sydney, Australia; CHU de Caen (O.C., B.M.), Caen, France; CNRS, CEA UMR6232 (N.T.-M., B.M.), Caen, France; Université de Caen Basse-Normandie (N.T.-M., B.M.), Caen, France; AP-HP, Hôpital Lariboisière (M.-G.B., C.T.), Service de Neurologie, Paris, France; and the Institut Universitaire de France (B.M.),...
書誌事項
- 公開日
- 2009-06
- DOI
-
- 10.1161/strokeaha.108.540633
- 公開者
- Ovid Technologies (Wolters Kluwer Health)
この論文をさがす
説明
<jats:p> <jats:bold> <jats:italic>Background and Purpose—</jats:italic> </jats:bold> Cerebral white matter hyperintensities (WMHs) are believed to be the consequence of small vessel disease, and it is uncertain whether their extent predicts the risk of dementia in patients with vascular disease history. </jats:p> <jats:p> <jats:bold> <jats:italic>Method—</jats:italic> </jats:bold> Brain MRI was performed in 226 participants of the PROGRESS study. WMH severity was assessed using a visual rating scale. During follow-up, patients were classified for incident severe cognitive deterioration (including dementia) using standard criteria. </jats:p> <jats:p> <jats:bold> <jats:italic>Results—</jats:italic> </jats:bold> Over 4-year follow-up, the incidence of severe cognitive deterioration ranged from 1.1 to 9.1 per 100 person-years in patients with respectively no or severe WMHs at baseline. In multivariable analysis, incident severe cognitive deterioration was associated with baseline severe WMHs (odds ratio=7.7, <jats:italic>P</jats:italic> <0.005). </jats:p> <jats:p> <jats:bold> <jats:italic>Conclusion—</jats:italic> </jats:bold> Higher WMH load is a strong predictor of dementia and cognitive decline in patients with cerebrovascular disease history. </jats:p>
収録刊行物
-
- Stroke
-
Stroke 40 (6), 2219-2221, 2009-06
Ovid Technologies (Wolters Kluwer Health)